Related Experiment Video
Updated: Jun 18, 2026
Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
Published on: September 1, 2018
GM-CSF-secreting vaccines for solid tumors
1The Johns Hopkins University and Sidney Kimmel Comprehensive Cancer Center, Department of Oncology, 1650 Orleans Street, Room 409, Bunting Blaustein Cancer Research Building, Baltimore, MD 21231-1000, USA. emensle@jhmi.edu
Abstract:
Whole tumor cells that secrete GM-CSF have been tested in clinical trials and have demonstrated early evidence of safety and clinical activity. The intradermal administration of these cells induces a massive infiltration of dendritic cells, which process and present tumor antigens to activate tumor-specific CD4+ and CD8+ T-cells. However, trial design flaws limit the phase III evaluation of this vaccine platform. Preclinical and clinical data suggest the development of GM-CSF-secreting tumor vaccines should be continued in combination with drugs that enhance vaccine activity by mitigating immune tolerance or augmenting costimulatory pathways of T-cell activation.
Insights
Whole tumor cells secreting granulocyte-macrophage colony-stimulating factor (GM-CSF) show safety and activity. Further development of these cancer vaccines is recommended with combination therapies to enhance T-cell activation.
Area of Science:
- Immunology
- Oncology
- Vaccine Development
Background:
- Whole tumor cells secreting granulocyte-macrophage colony-stimulating factor (GM-CSF) have shown early promise in clinical trials for cancer treatment.
- Intradermal administration of these cells effectively recruits dendritic cells to present tumor antigens, activating CD4+ and CD8+ T-cells.
Purpose of the Study:
- To evaluate the safety and clinical activity of GM-CSF-secreting whole tumor cell vaccines.
- To identify strategies for further development and optimization of this cancer vaccine platform.
Main Methods:
- Clinical trials involving intradermal administration of GM-CSF-secreting whole tumor cells.
- Assessment of immune cell infiltration, antigen presentation, and T-cell activation.
- Review of preclinical and clinical data to inform future trial design.
Main Results:
- Demonstrated early evidence of safety and clinical activity in patients.
- Observed massive infiltration of dendritic cells and activation of tumor-specific T-cells.
- Identified trial design limitations that hindered Phase III evaluation.
Conclusions:
- GM-CSF-secreting whole tumor cell vaccines represent a viable platform with demonstrated safety and immunomodulatory effects.
- Future development should focus on combination therapies to overcome immune tolerance and enhance T-cell costimulation for improved vaccine efficacy.
